Highlander Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,344 shares of the company’s stock after purchasing an additional 7,450 shares during the quarter. Teva Pharmaceutical Industries Limited comprises about 2.0% of Highlander Capital Management LLC’s portfolio, making the stock its 4th biggest holding. Highlander Capital Management LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $2,543,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of TEVA. Capital Research Global Investors increased its position in shares of Teva Pharmaceutical Industries Limited by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Capital World Investors increased its position in shares of Teva Pharmaceutical Industries Limited by 41.9% during the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after purchasing an additional 3,268,200 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Teva Pharmaceutical Industries Limited by 32.3% during the 2nd quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock worth $378,688,000 after purchasing an additional 2,782,257 shares during the last quarter. 56.75% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) is Highlander Capital Management LLC’s 4th Largest Position” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/09/teva-pharmaceutical-industries-limited-teva-is-highlander-capital-management-llcs-4th-largest-position.html.

Several research firms have weighed in on TEVA. BidaskClub raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Vetr lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 price target on the stock. in a research report on Tuesday, July 4th. Wells Fargo & Company reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. Jefferies Group LLC reaffirmed a “hold” rating and set a $33.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. Finally, Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Five investment analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $27.63.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 0.31% during mid-day trading on Monday, hitting $15.89. The company had a trading volume of 6,627,251 shares. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $45.85. The company’s 50-day moving average is $16.91 and its 200 day moving average is $26.76. The company’s market capitalization is $16.14 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.25 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.26 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 2.13%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is -15.36%.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.